Argenx halts late-stage Sjogren’s trial of Vyvgart
Argenx stopped a late-stage clinical trial of Vyvgart for Sjogren's disease due to lack of efficacy, with shares down 18% in European morning trading.
Argenx shares fell sharply after the biotech company stopped a late-stage clinical trial of its Vyvgart drug because it did not show enough efficacy for treating the autoimmune condition Sjogren's disease. Shares in Argenx were down 18% in European morning trading Thursday.